For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc9538Ja&default-theme=true
RNS Number : 9538J Oxford Biomedica PLC 29 April 2022
Directors Dealings / Market Share Purchases
Oxford, UK - 29 April 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the
Group") (LSE: OXB), a leading gene and cell therapy group, today
announces that Catherine Moukheibir, a Non-Executive Director of the Company,
has purchased shares in the Company.
As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved
at the 2021 Annual General Meeting, an additional fee of up to £50,000 per
annum may be paid to any Non-Executive Director recruited from or based
outside of the UK to reflect market levels of remuneration based for
Non-Executive Directors not based in the UK, subject to their agreement that
the after tax amount of this additional fee will be used to acquire Oxford
Biomedica shares at market value, which must be retained for at least 12
months from acquisition.
Catherine Moukheibir has purchased 2,467 ordinary shares of 50p each
("Ordinary Shares") in the Company on 29 April 2022 on the London Stock
Exchange at a price of 570.9p under the terms of a market purchase agreement.
Following this purchase Catherine Moukheibir holds 2,467 Ordinary Shares
representing 0.002% of the Company.
The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of Ordinary Shares
purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Catherine Moukheibir
2. Reason for the notification
a. Position/status Non-Executive Director
b. Initial notification /amendment Initial notification
3. Details of the issuer, emission allowance, market participant, auction
platform, auctioneer or auction monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument identification Oxford Biomedica plc Ordinary Shares of 50p each
code
GB00BDFBVT43
b. Nature of the transaction Purchase of ordinary shares
c. Currency GBP - British Pound
d. Price(s) and volume(s)
Price(s) Volume(s)
£5.71 2,467
e. Aggregated information
· Aggregated volume 2,467
· Price
· Aggregated total £5.70903
£14,084.18
f. Date of the transaction 2022-04-29
g. Place of the transaction London Stock Exchange, Main Market (XLON)
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFVRSAIAFIF